

ASX announcement

Scheme update – Volpara Scheme Resolution approved by Shareholders

Wellington, NZ, 12 April 2024: [Volpara Health Technologies Limited](#) (“Volpara” or “the Company”; ASX:VHT) advises that the scheme of arrangement (the “Scheme”), under which Lunit Inc. conditionally agreed to acquire all of the shares in Volpara, has been approved by shareholders at the scheme meeting today (“Scheme Meeting”). In total, 96.92% of all votes cast (excluding abstentions) were in favour of the Scheme. Details of the voting thresholds required to approve the Scheme and the voting results are set out below. The webcast of the meeting will be uploaded to Volpara’s website and will be viewable at www.volparahealth.com/investors/presentations/.”

The final steps in the Scheme process will now be undertaken, including applying to the High Court for final orders and satisfaction of other conditions (which are detailed in section 6.2 of the scheme booklet dated 13 March 2024 (“Scheme Booklet”). Volpara’s directors currently anticipate that all of these conditions will be satisfied.

If the High Court grants final orders approving the Scheme, and subject to the outstanding conditions being satisfied or (if capable of waiver) waived and the Scheme Implementation Agreement not being terminated, the last day of trading in Volpara shares will be 3 May 2024. Implementation of the Scheme and payment of the scheme consideration to shareholders is expected to occur on or about 21 May 2024. Shareholders will receive AU\$1.15 per Scheme share on the implementation date. More information on the timing of key implementation steps is set out on page 12 of the Scheme Booklet.

Volpara thanks all shareholders for their interest and engagement in this process.

Voting Results

To proceed, the Scheme required:

- 75% or more of the votes in each interest class¹ who were entitled to vote and who actually voted to have been voted in favour of the Scheme Resolution; and
- more than 50% of the total number of Volpara shares on issue to have been voted in favour of the Scheme Resolution.

At the Scheme Meeting, the voting results were as follows:²

Scheme Resolution: THAT the Scheme (the terms of which are described in the Scheme Booklet) be and is hereby approved.

¹ There was one interest class for the purposes of the Scheme Meeting. Further information regarding interest classes is set out in section 6.1(b) of the Scheme Booklet.

² For and against percentages calculated excluding abstentions.

	For	Against	Abstain
Interest class: All shareholders	172,908,889 shares 96.92%	5,497,340 shares 3.08%	206,268 shares
Total votes: Total number of shares on issue voted	172,908,889 shares 67.97%	5,497,340 shares 2.16%	206,268 shares

ENDS

For further information please contact:

Corporate enquiries

Teri Thomas, CEO & MD

Volpara Health Technologies

teri.thomas@volparahealth.com

t: +64 4 499 6029

Investor relations

Shareholder Information Line

Toll: 1300 513 794
 AU Toll-free: +61 2 9066 4082
 NZ Toll-free: +64 9 889 6570

Media enquiries

Clive Mathieson

Cato & Clive

clive@catoandclive.com

t: 61 411 888 425

About Volpara Health Technologies Limited (ASX: VHT)

Volpara Health Technologies makes software to save families from cancer. Volpara helps leading healthcare providers positively impact their patients and families around the world. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, improve and maintain mammogram quality, provide objective mammogram density, and speed up and smooth the arduous reporting necessary for mammography accreditation.

Volpara’s focus on customer value means that its AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staff shortages, Volpara’s software helps streamline operations and provides key performance insights that support continuous quality improvement.

A Certified B Corporation, Volpara is the preferred partner of leading healthcare institutions around the world. It maintains the most rigorous security certifications and holds over 100 patents and numerous regulatory registrations, including FDA clearance and CE marking. With a strong sales base in the United States and Australia, Volpara is based in Wellington, New Zealand, with an office in Seattle. For more information, visit www.volparahealth.com